RSCM
BCAX

Rock Springs Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Rock Springs Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9M Buy
535,286
+46,191
+9% +$1.03M 0.78% 42
2026
Q1 		$9.73M Buy
489,095
+60,000
+14% +$1.03M 0.57% 49
2025
Q4 		$7.22M Buy
429,095
+58,429
+16% +$998K 0.37% 61
2025
Q3 		$5.85M Buy
370,666
+34,596
+10% +$387K 0.34% 63
2025
Q2 		$3.12M Hold
336,070
– – 0.19% 71
2025
Q1 		$4.38M Sell
336,070
-109,905
-25% -$1.46M 0.25% 67
2024
Q4 		$7.77M Hold
445,975
– – 0.3% 68
2024
Q3 		$11.4M Buy
+445,975
New +$11.4M 0.37% 62

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rock Springs Capital Management's BCAX Position: Q2 2026 in Review

Rock Springs Capital Management increased its Bicara Therapeutics (BCAX) stake by 9.4% in Q2 2026, buying an estimated $1.03M and bringing the position to 535,286 shares worth $15.9M. The position accounts for 0.78% of the portfolio, ranked #42.

Rock Springs Capital Management first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. 171 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Rock Springs Capital Management held 535,286 shares of Bicara Therapeutics worth $15.9M as of Q2 2026.
  • Rock Springs Capital Management bought 46,191 Bicara Therapeutics shares in Q2 2026, an estimated $1.03M.
  • Bicara Therapeutics made up 0.78% of Rock Springs Capital Management's portfolio in Q2 2026, its #42 holding.
  • Rock Springs Capital Management first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 171 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.